Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, UPRES EA3859, SFR 4208, Université d'Angers, Angers, France.
Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, Nantes, France.
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101848. doi: 10.1016/j.clinre.2021.101848. Epub 2021 Dec 16.
Because of the high prevalence of chronic liver disease (CLD), it is crucial that general practitioners (GPs, in contact with the general population) and diabetologists (in contact with the most at-risk non-alcoholic fatty liver disease population) identify patients with advanced CLD requiring specialized management. The aim of this study was to evaluate CLD and CLD management awareness among diabetologists and GPs.
A questionnaire was sent to diabetologists within the Francophone Diabetes Society and to GPs in southern and western France. The questionnaire sounded participant characteristics and knowledge of CLD and its management.
678 questionnaires were completed by 500 GPs and 178 diabetologists. CLD prevalence was underestimated by 90% of GPs and 59% of diabetologists (p<0.001). For biological CLD follow-up, liver injury explorations (transaminases) were systematically included whereas severity explorations (prothrombin time, bilirubin) were prescribed for less than 50% of blood samples; GPs were more likely to prescribe severity explorations than diabetologists were (p<0.001). 74% of GPs and 97% of diabetologists (p<0.001) were familiar with non-invasive tests, Fibroscan and Fibrotest being the two most-frequently mentioned of them. In contrast, the simple blood test Fibrosis-4 was cited by less than 15% of GPs and 30% of diabetologists (p<0.001).
GPs and diabetologists have limited knowledge of CLD, despite its high prevalence. Continuing medical education among GPs and diabetologists is therefore necessary to enable the discovery of patients with advanced fibrosis and early management for them so as to avoid liver-related complications.
由于慢性肝病(CLD)的高患病率,全科医生(接触普通人群)和内分泌学家(接触高危非酒精性脂肪性肝病人群)识别需要专业管理的晚期 CLD 患者至关重要。本研究旨在评估内分泌学家和全科医生对 CLD 和 CLD 管理的认识。
向法语糖尿病学会的内分泌学家和法国南部和西部的全科医生发送了一份问卷。该问卷调查了参与者的特征以及他们对 CLD 及其管理的了解。
500 名全科医生和 178 名内分泌学家完成了 678 份问卷。90%的全科医生和 59%的内分泌学家低估了 CLD 的患病率(p<0.001)。对于生物 CLD 的随访,肝脏损伤检查(转氨酶)被系统地包括在内,而严重程度检查(凝血酶原时间、胆红素)则不到 50%的血液样本中被开处;全科医生比内分泌医生更有可能开严重程度检查(p<0.001)。74%的全科医生和 97%的内分泌学家(p<0.001)熟悉非侵入性检查,Fibroscan 和 Fibrotest 是他们最常提到的两种检查。相比之下,只有不到 15%的全科医生和 30%的内分泌医生(p<0.001)提到了简单的血液检查 Fibrosis-4。
尽管 CLD 的患病率很高,但全科医生和内分泌医生对 CLD 的了解有限。因此,有必要对全科医生和内分泌医生进行继续教育,以便发现患有晚期纤维化的患者并对其进行早期管理,从而避免与肝脏相关的并发症。